The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
Open accessAbstract
Introduction and Aims. As an antidepressant with sedative and anxiolytic properties, mirtazapine may be an appropriate pharmacotherapy for methamphetamine withdrawal. This study sought to examine whether mirtazapine improves retention and alleviates methamphetamine withdrawal symptoms in an out‐patient setting. Design and Methods. An out‐patient double‐blind, randomised placebo‐controlled trial of mirtazapine for the treatment of methamphetamine withdrawal was conducted (15 mg nocte for 2 days, 30 mg nocte for 12 days). Both groups were offered narrative therapy counselling. Measures recorded on days 0, 3, 7, 14 and 35 included: treatment retention, Amphetamine Cessation Symptoms Assessment, the Athens Insomnia Scale, the Brief Symptom Inventory, the Depression–Anxiety–Stress Scale (DASS), Severity of Dependence scale and the Opiate Treatment Index Drug Use subscale. Results. Thirty‐one participants were recruited (18 placebo, 13 mirtazapine) and 52% completed the 2‐week medication phase. No significant differences between the mirtazapine and placebo groups in retention, or any symptom measure were observed, except greater DASS–anxiety and longer sleep duration were measured at baseline among the mirtazapine group. Discussion and Conclusions. Results suggest that mirtazapine does not facilitate retention or recruitment in out‐patient methamphetamine withdrawal treatment, although recruitment may have been insufficient to identify a significant treatment effect. The potential role of narrative therapy for methamphetamine dependent patients deserves further exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Three medication studies showed significant reductions in craving ratings for MA: d-amphetamine 60mg/d for four weeks (48), combination of extended release naltrexone (380mg every 3 weeks) and bupropion (450mg q d; (49)) and rTMS (10HZ at left DPLFC, two 5-day sessions over 12 days (42)).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [42]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“one trial of repetitive transcranial magnetic stimulation (rTMS) (10HZ at left DPLFC, two 5-day sessions over 12 days (42))”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [42]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A third trial of mirtazapine (30mg/nocte for 14 days (43) showed no differences in withdrawal symptoms, though in this study all medications were self-administered at night and medication adherence problems may have interfered.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A third trial of mirtazapine (30mg/nocte for 14 days (43) showed no differences in withdrawal symptoms, though in this study all medications were self-administered at night and medication adherence problems may have interfered.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“No significant association with retention in out- patient withdrawal treatment”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Cruickshank, C.C. et al., 2008
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lovibond, P. F., & Lovibond, S. H. (1995) · Behaviour Research and Therapy · doi:10.1016/0005-7967(94)00075-u · Cited by 14,523
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
The brief symptom inventory: an introductory report.
Derogatis, L. R., & Melisaratos, N. (1983) · Psychological Medicine · doi:10.1017/s0033291700048017 · Cited by 6,650
Antony, M. M., Bieling, P. J., Cox, B. J., Enns, M. W., & Swinson, R. P. (1998) · Psychological Assessment · doi:10.1037/1040-3590.10.2.176 · Cited by 4,874
Athens Insomnia Scale: Validation of an instrument based on ICD-10 criteria
Soldatos, C. R., Dikeos, D. G., & Paparrigopoulos, T. J. (2000) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(00)00095-7 · Cited by 1,754
GOSSOP, M., DARKE, S., GRIFFITHS, P., HANDO, J., POWIS, B., HALL, W., & STRANG, J. (1995) · Addiction · doi:10.1046/j.1360-0443.1995.9056072.x · Cited by 1,343
Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine Abusers
Volkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., Sedler, M. J., Gatley, S. J., Hitzemann, R., Ding, Y.-S., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.377 · Cited by 984
A Review of the Pharmacological and Clinical Profile of Mirtazapine
Anttila, S. A. K., & Leinonen, E. V. J. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00198.x · Cited by 795
The diagnostic validity of the Athens Insomnia Scale
Soldatos, C. R., Dikeos, D. G., & Paparrigopoulos, T. J. (2003) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00604-9 · Cited by 661
Psychiatric Symptoms in Methamphetamine Users
Zweben, J. E., Cohen, J. B., Christian, D., Galloway, G. P., Salinardi, M., Parent, D., Iguchi, M., & Methamphetamine Treatment Project (2004) · The American Journal on Addictions · doi:10.1080/10550490490436055 · Cited by 468
Research works printed but not linked: 3
- McGregorC.Amphetamine withdrawal: nature time course and treatment[dissertation]. Adelaide South Australia:The University of Adelaide 2005.
- Derogatis LR., 1993, Brief symptom inventory administration, scoring, and procedures manual
- 10.1111/j.1360-0443.1997.tb02953.x · doi:10.1111/j.1360-0443.1997.tb02953.x · Paper page
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“However a more recent study failed to find any benefit of mirtazapine over placebo (Cruickshank et al., 2008) (Ib).”
BackgroundPharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175
“0 12 (27;27) 11 (23;23) 10 (23;23) 9 (26;24) 8 (27;24) 7 (26;25) 6 (26;27) 5 (27;22) 4 (27;27) 3 (25;23) 2 (28;27) 0 (30;30)”
A double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159
“Narrative therapy has also shown recent promise in methamphetamine users [44].”
BackgroundSleep and Antidepressant Treatment
Wichniak, A., Wierzbicka, A., & Jernajczyk, W. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523608 · Cited by 142
Pharmacotherapy of amphetamine‐type stimulant dependence: An update
Brensilver, M., Heinzerling, K. G., & SHOPTAW, S. J. (2013) · Drug and Alcohol Review · doi:10.1111/dar.12048 · Cited by 140
“[69] assessed mirtazapine in a randomised double-blind trial of 31 methamphetamine-dependent adults.”
BackgroundTreatment for amphetamine withdrawal
Shoptaw, S. J., Kao, U., Heinzerling, K., & Ling, W. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003021.pub2 · Cited by 120
Neural Substrates of Psychostimulant Withdrawal-Induced Anhedonia
D’Souza, M. S., & Markou, A. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_20 · Cited by 116
“N Cruickshank et al. (2008) (continued) compounds treated anhedonia, and most of the clinical studies were not successful in achieving their primary end point, which was to reduce relapse rates.”
BackgroundHeinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
“…antidepressant imipramine (Galloway et al., 1996), the GABA-ergic medications baclofen and gabapentin (Heinzerling et al., 2006), ondansetron, a 5HT3 receptor antagonist (Johnson et al., 2008), and mirtazapine, an antidepressant with adrenergic and serotonergic activity (Cruickshank et al., 2008).”
BackgroundChronic methamphetamine self-administration disrupts cortical control of cognition
Bernheim, A. P., See, R. E., & Reichel, C. M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.07.020 · Cited by 105
Treatments for Methamphetamine Abuse: A Literature Review for the Clinician
Brackins, T., Brahm, N. C., & Kissack, J. C. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426557 · Cited by 96
Dark Times: The Role of Negative Reinforcement in Methamphetamine Addiction
May, A. C., Aupperle, R. L., & Stewart, J. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00114 · Cited by 85
“A lack of group differences in reductions of depressive and anxiety symptoms have also been found following treatment with mirtazapine in conjunction with narrative therapy counseling compared to placebo (66).”
BackgroundA Review of Therapeutic Uses of Mirtazapine in Psychiatric and Medical Conditions
Alam, A., Voronovich, Z., & Carley, J. A. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13r01525 · Cited by 84
Psychostimulant addiction treatment
Phillips, K. A., Epstein, D. H., & Preston, K. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.04.002 · Cited by 85
“Cruickshank et al., 2008 Double-blind placebo-controlled randomized clinical trial: mirtazapine vs. placebo 31 participants (18 placebo, 13 mirtazapine) meeting DSM-IV criteria for amphetamine-type stimulant dependence and reported use of amphetamine or methamphetamine during the prior 72 hours;…”
BackgroundMethodThe ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
New horizons for therapeutics in drug and alcohol abuse
Jupp, B., & Lawrence, A. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.002 · Cited by 85
Miles, S. W., Sheridan, J., Russell, B., Kydd, R., Wheeler, A., Walters, C., Gamble, G., Hardley, P., Jensen, M., Kuoppasalmi, K., et al. (2013) · Addiction · doi:10.1111/add.12109 · Cited by 63
“Possible benefits have been shown for methylphenidate [17], naltrexone [18], modafinil [15], dexamphetamine [14,16] and mirtazapine [11,19].”
BackgroundThe Efficacy of Mirtazapine in the Treatment of Cocaine Dependence with Comorbid Depression
Afshar, M., Knapp, C. M., Sarid‐Segal, O., Devine, E. G., Colaneri, L. S., Tozier, L., Waters, M., Putnam, M. A., & Ciraulo, D. A. (2012) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2011.644002 · Cited by 62
“In contrast, in a third study when compared with placebo administration, mirtazapine treatment did not significantly reduce methamphetamine use or improve symptoms of withdrawal from this drug (16).”
A Review of Methamphetamine Dependence and Withdrawal Treatment: A Focus on Anxiety Outcomes
Hellem, T. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.08.011 · Cited by 55
Rezaei, F., Emami, M., Zahed, S., Morabbi, M.-J., Farahzadi, M., & Akhondzadeh, S. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0092-y · Cited by 54
“In the last decade, many medications have been used for treatment of methamphetamine dependence including modafinil, antidepressants, ondansetron, risperidone, aripiprazole, baclofen, topiramate, N-acetyl cysteine, naltrexone, and gabapentin, but none demonstrated consistent efficacy [2,10,13,18-25].”
Graves, S. M., Rafeyan, R., Watts, J., & Napier, T. C. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.013 · Cited by 54
“…placebo controlled study assessing the use of mirtazapine for the management of acute methamphetamine withdrawal and found no significant differences between mirtazapine and placebo groups in study retention and an increase in anxiety and sleep duration with mirtazapine (Cruickshank et al., 2008).”
BackgroundA review of treatment options for co-occurring methamphetamine use disorders and depression
Hellem, T. L., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000058 · Cited by 51
Mirtazapine prevents induction and expression of cocaine-induced behavioral sensitization in rats
Salazar‐Juárez, A., Barbosa-Méndez, S., Jurado, N., Hernández-Miramontes, R., Leff, P., & Antón, B. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.010 · Cited by 51
“However, others trial have reported that mirtazapine has failed to significantly reduce the methamphetamine or cocaine use in subjects with comorbid depressive disorders (Afshar et al., 2012; Cruickshank et al., 2008).”
Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study
Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Dual Diagnosis · doi:10.1080/15504263.2015.1100471 · Cited by 49
“…dependence (Colfax et al., 2011; Elkashef et al., 2008; Galloway, Newmeyer, Knapp, Stalcup, & Smith, 1996; Heinzerling et al., 2010; Shoptaw et al., 2008; Shoptaw et al., 2006) or withdrawal (Cruickshank et al., 2008) have generally shown that antidepressants are not an adequate treatment option.”
BackgroundAcheson, L. S., Williams, B. H., Farrell, M., McKetin, R., Ezard, N., & Siefried, K. J. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13511 · Cited by 49
“Four studies reported withdrawal outcomes, of which three (with 93 participants) were included in the metaanalysis [49, 50, 54].”
BackgroundMethodInfluentialAbdulrahim, D., & Bowden‐Jones, O. (2015) · Cited by 144
Zorick, T. S., Sugar, C. A., Hellemann, G., SHOPTAW, S. J., & London, E. D. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.04.015 · Cited by 44
Wodarz, N., Krampe-Scheidler, A., Christ, M., Fleischmann, H., Looser, W., Schoett, K., Vilsmeier, F., Bothe, L., Schaefer, C., & Gouzoulis‐Mayfrank, E. (2017) · Pharmacopsychiatry · doi:10.1055/s-0042-123752 · Cited by 43
Clinical management of psychostimulant withdrawal: review of the evidence
Li, M. J., & Shoptaw, S. J. (2023) · Addiction · doi:10.1111/add.16093 · Cited by 39
Härtel-Petri, R., Krampe-Scheidler, A., Braunwarth, W.-D., Havemann-Reinecke, U., Jeschke, P., Looser, W., Mühlig, S., Schäfer, I., Scherbaum, N., Bothe, L., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-105500 · Cited by 39
“There were signs of an improvement in the sleep disorder and an overall increase in sleep duration on mirtazapine [57].”
BackgroundCrosstalk between Sleep Disturbance and Opioid Use Disorder: A Narrative Review.
Fathi, H. R., Yoonessi, A., Khatibi, A., Rezaeitalab, F., & Ardanı, A. R. (2020) · PubMed Central · doi:10.22122/ahj.v12i2.249 · Cited by 39
Pennay, A. E., & Lee, N. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2010.00240.x · Cited by 35
“In an inpatient setting, mirtazapine showed significant improvements over placebo on a number of symptoms of withdrawal over 14 days [38], and in an outpatient setting mirtazapine was no more effective than placebo in reducing withdrawal symptoms over 12 days [39].”
BackgroundLee, N., Pennay, A. E., Hester, R., McKetin, R., Nielsen, S., & Ferris, J. (2012) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2012.00473.x · Cited by 35
“[14] concluded that 12 days of mirtazapine, a tricyclic antidepressant, in an outpatient setting, was no more effective than placebo in reducing methamphetamine withdrawal symptoms; while over a decade ago, treatment with amineptine, an atypical tricyclic antidepressant, showed some improvements in mood and energy ove…”
BackgroundPharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups
Soares, E. F. P., & Pereira, F. C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1681970 · Cited by 34
Is immunotherapy an opportunity for effective treatment of drug addiction?
Zalewska-Kaszubska, J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.079 · Cited by 36
Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets
Yates, J. R. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s431273 · Cited by 32
“138 This latter finding suggests that mirtazapine may not be beneficial for individuals actively going through withdrawal.”
BackgroundVoigt, R. M., Mickiewicz, A. L., & Napier, T. C. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.07.009 · Cited by 30
Mirtazapine attenuates cocaine seeking in rats
Barbosa-Méndez, S., Leff, P., Caballero, A. A., Hernández-Miramontes, R., Heinze, G., & Salazar‐Juárez, A. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.03.021 · Cited by 30
Medications between psychiatric and addictive disorders
Lalanne, L., Lutz, P.-É., Trojak, B., Lang, J.-P., Kieffer, B. L., & Bacon, É. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.10.009 · Cited by 26
Voigt, R. M., & Napier, T. C. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00092 · Cited by 24
Acheson, L. S., Ezard, N., Lintzeris, N., Dunlop, A. J., Brett, J., Rodgers, C., Gill, A., Christmass, M. A., McKetin, R., Farrell, M., et al. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109692 · Cited by 23
Degenhardt, L. J., Baker, A., & Maher, L. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801956538 · Cited by 23
“Although the paper by Cruickshank and colleagues found that mirtazepine was not helpful in reducing methamphetamine withdrawal severity, this small study suggests that narrative therapy may be an acceptable counselling approach for methamphetamine users [15].”
ResultNovel Pharmacological Approaches to Drug Abuse Treatment
Edens, E. L., Massa, A. A., & Petrakis, I. L. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_29 · Cited by 22
“For example, neither baclofen, gabapentin, ondansetron, nor mirtazapine have been found superior to placebo in decreasing cocaine use or cocaine cravings (Cruickshank et al. 2008; Heinzerling et al. 2006; Johnson et al. 2008).”
BackgroundAlcohol and other drug withdrawal: practice guidelines.
Kenny, P., Swan, A., Berends, L., Jenner, L., Hunter, B., & Mugavin, J. (2009) · Cited by 20
Wu, M., Satogami, K., Liang, C., Stubbs, B., Carvalho, A. F., Brunoni, A. R., Su, K., Tu, Y., Wu, Y., Chen, T., et al. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13452 · Cited by 17
Effect of Mirtazapine on Craving in Cocaine-Dependent Patients
Alvarado, R. N., Gonzalez, M., Lima, C., Marín-Navarrete, R., Barbosa-Méndez, S., & Salazar‐Juárez, A. (2021) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-021-00547-6 · Cited by 19
Barbosa-Méndez, S., Matus-Ortega, M., & Salazar‐Juárez, A. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.08.017 · Cited by 10
Arora, S., & Vohora, D. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12566 · Cited by 9
Management of withdrawal from alcohol and other drugs
Lintzeris, N., Sunjic, S., Demirkol, A., Branezac, M., Ezard, N., Siefried, K. J., Acheson, L. S., Bascombe, F., Tremonti, C., & Haber, P. (2019) · doi:10.57022/mjjp9930 · Cited by 10
Zhao, C., Lou, Z., Zimmer, B., Yu, Z., Li, P., Ma, B., Sun, Y., Huang, K., Zhou, W., & Liu, Y. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.06.011 · Cited by 8
“In addition, the treatment effects of 5-HT receptor antagonists, ondansetron and mirtazapine, have also been clinically investigated in METH-dependent patients (Cruickshank et al., 2008; Johnson et al., 2008).”
Grau‐López, L., Grau‐López, L., Daigre, C., Palma-Álvarez, R. F., Rodríguez-Cintas, L., Ros‐Cucurull, E., & Roncero, C. (2017) · Substance Use & Misuse · doi:10.1080/10826084.2017.1402056 · Cited by 6
“…patients with substance use disorders in previous studies (Chakravorty et al., 2014; Afshar et al., 2012; Rubio et al., 2011; Richey & Krystal, 2011; Kolla et al., 2011; Friedmann et al., 2008; Cruickshank et al., 2008; Terán et al., 2008; Brower et al., 2008; Johnson et al., 2008; Malcolm Table .”
BackgroundInfluentialAlipour, M., Jafarian, M., Sisakht, R. R., Mokri, A., Gorji, A., Zarrindast, M., Lorestani, F., & Razaghi, E. M. (2021) · European Addiction Research · doi:10.1159/000515398 · Cited by 5
Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine
Garza, R. D. L., Galloway, G., Newton, T. F., Mendelson, J. E., Haile, C. N., Dib, E., Hawkins, R. Y., Chen, C. A., Mahoney, J. J., Mojsiak, J., et al. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.11.013 · Cited by 5
“Medications that target NE attenuate stimulant-induced positive subjective drug effects, decrease drug use, and attenuate withdrawal symptoms (Colfax et al., 2011; Cruickshank et al., 2008; Gaval-Cruz and Weinshenker, 2009; Haile et al., 2012a; Newton et al., 2009, 2012).”
BackgroundMirtazapine: Multitarget strategies for treating substance use disorder and depression
Barbosa-Méndez, S., Becerril-Villanueva, L. E., Ponce-Regalado, M. D., & Salazar‐Juárez, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00043-8 · Cited by 6
Managing treatment-resistant depression with comorbid substance use disorders
Stubbs, K. R., Bezooyen, J. V., & Tang, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00031-1 · Cited by 3
Dwoskin, L. P., Glaser, P. E. A., & Bardo, M. T. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_52 · Cited by 2
Theta burst stimulation (TBS) in methamphetamine use disorder: a meta-analysis and systematic review
Rakesh, G., Adams, T. G., Ballard, D. H., McLouth, C. J., & Rush, C. R. (2025) · Journal of Addictive Diseases · doi:10.1080/10550887.2025.2541165 · Cited by 1
Insomnia is associated with psychological distress in individuals with methamphetamine dependence
Matepi, Q. G. J., Clifford, B., Acheson, L. S., McKetin, R., Montebello, M. E., Siefried, K. J., Chan, D. K. E., Olsen, N., May, R., & Ezard, N. (2025) · Australasian Psychiatry · doi:10.1177/10398562251406035 · Cited by 1
“18 Sustained methamphetamine use has been linked to tolerance to its sleep-disrupting effects, while insomnia and negative affect may accompany continued use.”
Self-citationKarami, F., Assarian, F., Ghoreishi, F. S., & Sehat, M. (2020) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.97550 · Cited by 1
Pharmacological management of disrupted sleep due to Methamphetamine use: a literature review
Kaur, J., & Garg, K. (2020) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2020.11.00684 · Cited by 1
Perinatal Methamphetamine Use: A Review of the Literature
Hickert, A., Rowley, B., & Doyle, M. (2021) · Psychiatric Annals · doi:10.3928/00485713-20210303-01 · Cited by 1
Crystal meth abuse: A pretty state of affairs
Goyal, N., & Kaur, G. (2023) · AIP conference proceedings · doi:10.1063/5.0115624 · Cited by 1
Horton, D. B. (2012) · UKnowledge (University of Kentucky)
Methamphetamine withdrawal: clinical profile, assessment and treatment
Cruickshank, C. (2010) · UWA Profiles and Research Repository (UWA)
Self-citationCao, Z. (2014) · UKnowledge (University of Kentucky)
Pharmacological Treatments for Methamphetamine Use Disorder: A Systematic Review
Evans, J. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/q5np-jm02
Wodarz, N., Christ, M., Fleischmann, H., Looser, W., Schoett, K., Vilsmeier, F., Krampe-Scheidler, A., Schaefer, C., Bothe, L., Mühlig, S., et al. (2019) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000615
المَواد اَلنَفسیة وَالأَسس اَلبیولوجیة لَتعاطیها
المکارم, ف. م. أ. (2017) · دراسات نفسية · doi:10.21608/psj.2017.97184
Jang, K. (2024) · Journal of Drugs Addiction & Therapeutics · doi:10.47363/jdat/2024(5)148
“Author Contribution KJ: searched literature, wrote the manuscript; EG: searched literature, wrote part of the manuscript; ADT: designed the aims, method, searched literature, wrote the manuscript, supervised the team.”
MethodPulido-Saavedra, A., Borelli, A., Kitaneh, R., Alrafayia, M., Khave, L. J., Funaro, M. C., Potenza, M. N., & Angarita, G. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2446623
“The results did not show significant differences between groups for retention ( p > 0.05) or withdrawal signs ( p > 0.05) [66].”
InfluentialKokain, Amphetamin und andere Stimulanzien
Koopmann, A., Fehr, C., & Kiefer, F. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_70
Treatment During Abstinence from Methamphetamine in a Rat Model of Methamphetamine Use Disorder
Baek, J. J. (2022) · Purdue University Indianapolis (Indiana University) · doi:10.7912/c2/3068 · Cited by 1
Bourtin, I. G., Calvillo, D. J., Badawi, J. C., Schmitz, J. M., Lane, S. D., Yoon, J. H., & Webber, H. E. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113125
Greenwald, M. K., Grasser, L. R., & Winston, J. R. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1899599
Metadata
- Authors
- CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D.
- Affiliations
- The University of Western Australia (AU)
- UNSW Sydney (AU)
- Mental Health Commission (AU)
- Corresponding author
- CRUICKSHANK, CHRISTOPHER C.
- Venue
- Drug and Alcohol Review
- Publisher
- Wiley
- Published
- 2008-05
- Volume
- 27
- Issue
- 3
- Pages
- 326-333
- ISSN
- 0959-5236 (ISSN-L)
- 1465-3362
- OpenAlex
- W2142454789
- Cited by
- 74
- References
- 46
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 1 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 3 · 2017: 6 · 2016: 4 · 2015: 6 · 2014: 2 · 2013: 4 · 2012: 8
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Drug and Alcohol Review (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- mirtazapine, methamphetamine withdrawal, treatment retention, narrative therapy, outpatient care, antidepressants, substance dependence, anxiety, sleep duration
- MeSH terms
- Mirtazapine, Adult, Ambulatory Care, Central Nervous System Stimulants, Antidepressive Agents, Tricyclic, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Methamphetamine, Mianserin, Psychiatric Status Rating Scales, Severity of Illness Index, Substance Withdrawal Syndrome, Time Factors, Amphetamine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.